Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.

Zenz S, Regittnig W, Boulgaropoulos B, Augustin T, Brunner M, Korsatko S, Münzker J, Narath SH, Raml R, Magnes C, Pieber TR

The Journal of clinical endocrinology and metabolism1 Aug 2022Cited by 9 (Europe PMC)

PMID35833597DOI10.1210/clinem/dgac369PepBankPUB-35833597

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, endogenous glucose production during a hypoglycemic clamp was similar with liraglutide and placebo.
In plain wordsIn adults with type 1 diabetes, liver sugar release during low blood sugar was similar with liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeEndogenous glucose production during hypoglycemic clamp
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
The responses of endogenous glucose production (EGP) and rate of peripheral glucose disposal (Rd) were similar for liraglutide and placebo treatment during the clamp.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359701
02HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, the rate of peripheral glucose disposal during a hypoglycemic clamp was similar with liraglutide and placebo.
In plain wordsIn adults with type 1 diabetes, the rate at which tissues took up sugar was similar with liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changePeripheral glucose disposal during hypoglycemic clamp
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
The responses of endogenous glucose production (EGP) and rate of peripheral glucose disposal (Rd) were similar for liraglutide and placebo treatment during the clamp.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359702
03HumanRandomized controlled trialSafety outcome
In adults with C-peptide-positive type 1 diabetes, the number of hypoglycemic events was similar with liraglutide and placebo.
In plain wordsIn adults with type 1 diabetes, the number of low blood sugar events was similar with liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeNumber of hypoglycemic events
Study
n = 14
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
The numbers of hypoglycemic events were similar in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359703
04HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, mean glucagon was significantly lower with liraglutide than placebo at the 5.5 mmol/L plasma glucose plateau.
In plain wordsIn adults with type 1 diabetes, glucagon was lower with liraglutide than with placebo at normal blood sugar.
Peptide
Liraglutide
Outcome
DecreaseGlucagon level at 5.5 mmol/L plateau
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
At the clamp, mean glucagon levels were significantly lower at PG plateau 5.5 mmol/L in the liraglutide than in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359704
05HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, glucagon responses to hypoglycemia were similar with liraglutide and placebo.
In plain wordsIn adults with type 1 diabetes, the glucagon response to low blood sugar was similar with liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeGlucagon response to hypoglycemia
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
but showed similar responses to hypoglycemia in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359705
06HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, mean C-peptide was significantly higher with liraglutide at the 5.5 and 3.5 mmol/L plateaus, without a matching change in glucose production or disposal.
In plain wordsIn adults with type 1 diabetes, C-peptide was higher after liraglutide at two blood sugar levels, but this did not change sugar handling.
Peptide
Liraglutide
Outcome
IncreaseC-peptide level at 5.5 and 3.5 mmol/L plateaus
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
Mean C-peptide levels were significantly higher at PG-plateaus 5.5 and 3.5 mmol/L after liraglutide treatment, but this effect was not reflected in EGP and Rd.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359706
07HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, HbA1c was lower after liraglutide treatment.
In plain wordsIn adults with type 1 diabetes, HbA1c was lower after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseHemoglobin A1c
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c and body weight were lower, and a trend for reduced insulin was seen after liraglutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359707
08HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, body weight was lower after liraglutide treatment.
In plain wordsIn adults with type 1 diabetes, body weight was lower after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 14
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c and body weight were lower, and a trend for reduced insulin was seen after liraglutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359708
09HumanRandomized controlled trialEfficacy outcome
In adults with C-peptide-positive type 1 diabetes, insulin use showed only a trend toward reduction after liraglutide treatment.
In plain wordsIn adults with type 1 diabetes, insulin use showed only a trend to fall after liraglutide.
Peptide
Liraglutide
Outcome
No significant changeInsulin dose
Study
n = 14
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · injection · 12 weeksAs given in this study (human).
Source sentences
Summary
a trend for reduced insulin was seen after liraglutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, crossover study.
Summary · context
Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L.
Report a problemFND-3583359709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02408705

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

Medical University of Grazn = 14Jan 2015 to May 2016

Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 12 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.